175 related articles for article (PubMed ID: 1612008)
1. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
[TBL] [Abstract][Full Text] [Related]
2. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily.
Wilson CA; di Clemente N; Ehrenfels C; Pepinsky RB; Josso N; Vigier B; Cate RL
Mol Endocrinol; 1993 Feb; 7(2):247-57. PubMed ID: 8469238
[TBL] [Abstract][Full Text] [Related]
3. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.
Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR
Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479
[TBL] [Abstract][Full Text] [Related]
4. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
5. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
6. Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects.
Ragin RC; Donahoe PK; Kenneally MK; Ahmad MF; MacLaughlin DT
Protein Expr Purif; 1992 Jun; 3(3):236-45. PubMed ID: 1392620
[TBL] [Abstract][Full Text] [Related]
7. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells.
Kim JH; Seibel MM; MacLaughlin DT; Donahoe PK; Ransil BJ; Hametz PA; Richards CJ
J Clin Endocrinol Metab; 1992 Sep; 75(3):911-7. PubMed ID: 1517385
[TBL] [Abstract][Full Text] [Related]
8. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
9. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes.
Catlin EA; Uitvlugt ND; Donahoe PK; Powell DM; Hayashi M; MacLaughlin DT
Metabolism; 1991 Nov; 40(11):1178-84. PubMed ID: 1943746
[TBL] [Abstract][Full Text] [Related]
10. Identification of a receptor for human müllerian inhibiting substance.
Catlin EA; Ezzell RM; Donahoe PK; Gustafson ML; Son EV; MacLaughlin DT
Endocrinology; 1993 Dec; 133(6):3007-13. PubMed ID: 8243329
[TBL] [Abstract][Full Text] [Related]
11. Insensitivity of the chick embryo müllerian duct to human recombinant müllerian-inhibiting substance.
Weniger JP; Cate RL; Zeis A
J Mol Endocrinol; 1992 Feb; 8(1):73-7. PubMed ID: 1543536
[TBL] [Abstract][Full Text] [Related]
12. Androgen stimulation of nucleotide pyrophosphatase during mullerian duct regression.
Fallat ME; Hutson JM; Budzik GP; Donahoe PK
Endocrinology; 1984 May; 114(5):1592-8. PubMed ID: 6143657
[TBL] [Abstract][Full Text] [Related]
13. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
15. [Antagonistic actions of testosterone and the anti-mullerian hormone on the mullerian duct of the chick embryo in culture in vitro].
Weniger JP; Zeis A
Arch Anat Microsc Morphol Exp; 1982; 71(2):99-106. PubMed ID: 6897160
[TBL] [Abstract][Full Text] [Related]
16. Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids.
Kuroda T; Lee MM; Ragin RC; Hirobe S; Donahoe PK
Endocrinology; 1991 Dec; 129(6):2985-92. PubMed ID: 1954882
[TBL] [Abstract][Full Text] [Related]
17. Sex-specific fetal lung development and müllerian inhibiting substance.
Catlin EA; Powell SM; Manganaro TF; Hudson PL; Ragin RC; Epstein J; Donahoe PK
Am Rev Respir Dis; 1990 Feb; 141(2):466-70. PubMed ID: 2301861
[TBL] [Abstract][Full Text] [Related]
18. Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive.
Maggard MA; Catlin EA; Hudson PL; Donahoe PK; MacLaughlin DT
Metabolism; 1996 Feb; 45(2):190-5. PubMed ID: 8596488
[TBL] [Abstract][Full Text] [Related]
19. New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity.
Lorenzo HK; Teixeira J; Pahlavan N; Laurich VM; Donahoe PK; MacLaughlin DT
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jan; 766(1):89-98. PubMed ID: 11820299
[TBL] [Abstract][Full Text] [Related]
20. [Müllerian inhibiting substance].
Shima H
Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1747-58. PubMed ID: 8255037
[No Abstract] [Full Text] [Related]
[Next] [New Search]
